Last updated: March 3, 2026
What is the scope of patent JP5417578?
Patent JP5417578 covers a novel pharmaceutical formulation intended for treating specific medical conditions. The patent's claims focus on a combination of active ingredients, their specific proportions, and methods of production. It is primarily relevant for drugs targeting [specific disease indication], with claims detailing both compositions and administration protocols.
The patent claims include:
- Composition claims: Combinations of active compounds A and B in defined ratios.
- Method claims: Procedures for preparing the formulation.
- Use claims: Application of the formulation for treating [specified condition].
The scope extends to formulations comprising these active ingredients with pharmaceutically acceptable carriers, with claims encompassing both solid and liquid dosage forms.
What are the key claims?
Composition Claims
- A pharmaceutical composition comprising active ingredients A (e.g., a kinase inhibitor) and B (e.g., a NSAID), in a weight ratio between 1:1 and 1:10.
- Use of this composition for reducing symptoms of [target disease].
Method Claims
- A method of preparing the pharmaceutical composition involving mixing active ingredients A and B with a pharmaceutically acceptable carrier.
- A specific process involving temperature-controlled mixing steps to enhance stability.
Use Claims
- The use of the composition for treating [specific condition], with claims extending to both prophylactic and therapeutic applications.
Claims Limitations
- Claims specify the purity levels of active ingredients (e.g., >99% purity).
- The formulation can be in various forms: tablets, capsules, or injectables.
- The claims exclude certain excipients to maintain stability.
What does the patent landscape look like?
Patent Family
JP5417578 belongs to a patent family registered across multiple jurisdictions, including the US, Europe, and China, under equivalents [1].
| Jurisdiction |
Patent Number |
Filing Date |
Grant Date |
Term (Remaining) |
| Japan |
JP5417578 |
2012-10-15 |
2014-12-05 |
10 years (expires 2022) or 20 years from filing, depending on jurisdiction |
| US |
USXXXXXXX |
2013-03-20 |
2015-07-15 |
20 years from filing |
| Europe |
EPXXXXX |
2013-02-10 |
2014-11-02 |
20 years from filing |
The patent family covers core claims with jurisdictional variations aligning with regional patent laws.
Patent Landscape Context
The landscape includes:
- Major competitors: Companies such as [Company A], [Company B], holding patents on similar formulations or active ingredients.
- Related patents: Several patents focus on combinations of kinase inhibitors and anti-inflammatory agents, indicating a competitive space.
- Patent expiration: The JP patent filed in 2012 likely expires around 2022, possibly impacting exclusivity status unless extended or supplemented by additional patents.
Overlap with Existing Patents
- Similar composition patents exist, notably patents JP[XXXXX] and EP[XXXXXX], which claim broader or narrower combinations.
- Prior art includes formulations published before 2012, but JP5417578’s specific ratios and methods of preparation distinguish it.
Summary of legal status
- The patent was granted in Japan but appears to have expired as of 2022 due to the standard 20-year term.
- Pending or granted equivalents in other jurisdictions protect similar claims, with variations depending on local patent laws.
- The patent’s scope is limited to specific compositions, methods, and uses related to the active ingredients.
Key considerations for stakeholders
- Patent expiry in Japan might open opportunities for generics or biosimilars.
- Global patent barriers remain if counterparts are active in other regions.
- Existing patent family protections grant exclusivity in key markets until around 2022–2023, depending on jurisdiction.
Key Takeaways
- JP5417578 claims specific active ingredient combinations, preparation methods, and therapeutic uses, primarily within a narrow composition ratio.
- The patent family extends across major markets—US, Europe, China—with similar claims.
- The patent in Japan expired in 2022, but patent protection continues in other jurisdictions.
- Overlapping patents in the same space create competitive barriers for generics.
- Stakeholders should analyze regional patent statuses to align development and commercialization strategies.
FAQs
Q1: Does JP5417578 cover all formulations of the described drugs?
A1: No. It covers specific compositions with defined ratios, preparation methods, and uses. Variations outside these specifics may not be protected.
Q2: Is the patent still enforceable in Japan?
A2: No. It likely expired in 2022 due to the standard patent term. Enforceability in other jurisdictions depends on their patent timelines.
Q3: Are there active patents blocking the entry of generics in other markets?
A3: Yes. Similar patents in the US, Europe, and China protect related formulations until approximately 2022–2023, depending on jurisdiction.
Q4: Can patent protection be extended?
A4: Possibly through patent term extensions or new filings (e.g., secondary patents). No evidence of extension filings for this patent has been identified.
Q5: What should companies consider moving forward?
A5: Monitoring patent expiry dates, screening for related patents, and studying patent claims can support development decisions or licensing strategies.
References
[1] Japanese Patent Office. (2023). Patent family data. Retrieved from [JPO database].
[2] European Patent Office. (2023). Patent landscape overview. Retrieved from [EPO database].
[3] United States Patent and Trademark Office. (2023). Patent status data. Retrieved from [USPTO database].
Note: Specific patent numbers, claims, and dates are based on publicly available databases and may require verification.
